-- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced updated clinical data from its ongoing Phase I/II trial of AMT-060, its proprietary, investigational gene therapy, in patients with severe hemophilia B.
-- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced updated clinical data from its ongoing Phase I/II trial of AMT-060, its proprietary, investigational gene therapy, in patients with severe hemophilia B.